Zydus Lifesciences Launches India’s First Quadrivalent Flu Vaccine

Zydus Lifesciences has introduced a new vaccine to shield against the latest strain of the influenza virus. The Ahmedabad-based pharmaceutical company announced on Wednesday that it has launched India’s first quadrivalent influenza vaccine, VaxiFlu-4, based on WHO’s recommended composition.

VaxiFlu-4: Protection Against 4 Virus Strains

VaxiFlu-4 is a quadrivalent inactivated influenza vaccine that provides seasonal protection against 4 different virus strains, covering both Influenza A and Influenza B. This broader coverage helps reduce the risk of vaccine mismatch, ensuring better immunity.

Regulatory Clearance and Development

The vaccine has been approved by the Central Drug Laboratory (CDL) and was developed at Zydus’s Vaccine Technology Centre (VTC) in Ahmedabad. The company highlighted the importance of preventive healthcare and how vaccines play a crucial role in improving quality of life.

Need for Affordable Flu Vaccines in India

Zydus Lifesciences MD Sharvil Patel emphasised the growing need for affordable, high-quality vaccines in India to tackle healthcare challenges. He stated that annual immunisation with vaccines like VaxiFlu-4 can help prevent flu outbreaks and protect public health.

Influenza: A Growing Public Health Concern

Influenza is a contagious respiratory infection that spreads through airborne droplets from coughing, sneezing, or direct contact. It can cause mild to severe illness, with high-risk groups such as young children, the elderly, and individuals with chronic conditions being more vulnerable.

According to the WHO (World Health Organization), seasonal influenza causes between 2.9 lakh to 6.5 lakh deaths globally every year. With frequent outbreaks, controlling influenza has become a major public health challenge.

By launching VaxiFlu-4, Zydus aims to strengthen flu prevention and improve healthcare accessibility in India.

About Zydus Lifesciences Limited

Zydus Lifesciences Limited, previously known as Cadila Healthcare Ltd, is an Indian multinational pharmaceutical company based in Ahmedabad. It focuses on manufacturing generic medicines and was ranked 100th in the Fortune India 500 list in 2020.

As of February 27, 2025, at 11:16 AM IST, Zydus Lifesciences share price is trading at ₹879.95, down 0.34% (-₹3.00). The stock opened at ₹887.45, reached a high of ₹905.00, and a low of ₹872.35. The company’s market capitalisation stands at ₹88,540 crore, with a P/E ratio of 19.54 and a dividend yield of 0.34%. The 52-week high is ₹1,324.30, while the 52-week low is ₹855.10.

Conclusion

With VaxiFlu-4, Zydus enhances flu prevention in India, ensuring broader immunity and improved healthcare access.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.